Shares of Granules India Ltd had been buying and selling 2% increased on 23 June after the corporate introduced receiving one commentary from the US FDA for its Hyderabad facility.
In its regulatory submitting, the corporate mentioned, “The corporate’s API Unit-I facility situated at Bonthapally Village, Sangareddy District, Hyderabad, Telangana, India has accomplished a USFDA inspection from 16 June, 2025 to twenty June, 2025 with one 483 commentary.”
The company will reply to this commentary inside the timeframe specified, it acknowledged.
The Bonthapally plant is among the world’s largest single-site Paracetamol API manufacturing services by way of quantity. Together with Paracetamol APIs, the corporate has arrange manufacturing traces for Metformin and Guaifenesin APIs on the identical website.
On 02 September 2024 and 07 April 2025, the shares reached a 52-week excessive of Rs 724.55 and a low of Rs 412.05, respectively.
At 12:06 pm, the shares of Granules India had been buying and selling 2.01% increased at Rs 497.15 on NSE.
Uninterested in guessing shares to commerce in day by day?
Unicorn Alerts empowers you with highly effective instruments like day by day inventory scans for Intraday, Swing & Investing, Market Predictions and way more. Obtain the Unicorn Alerts app at present and take management of your investments!
